Medarex also announced that results from the MDX-1100 Phase 1 trials
will be presented at the Digestive Disease Week (DDW) meeting, being held
May 17 - 22, 2008 in San Diego. The following abstracts are expected to be
the subject of presentations at the DDW 2008 conference:
-- "A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and
Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal
Antibody, in Healthy Subjects" (Abstract #T1145) - Poster presentation
on May 20, 2008 from 12:00 to 2:00 PM CDT.
-- "A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of MDX-1100,
a High-Affinity, Neutralizing, Fully Human IgG1k Anti-CXCL10 (IP10)
Monoclonal Antibody, in Ulcerative Colitis" (Abstract #704) - Oral
presentation on May 20, 2008 from 3:00 to 3:15 PM CDT.
-- "CXCL10 Expression and Biological Activities in Inflammatory Bowel
Disease" (Abstract #W1170) - Poster presentation on May 21, 2008 from
12:00 to 2:00 PM CDT.
These presentations support the development of MDX-1100 for the treatment of inflammatory diseases such as ulcerative colitis and rheumatoid arthritis.
MDX-1100 is a fully human antibody that targets CXCL10 (also known as IP-10), a chemokine expressed in association with multiple inflammatory disease indications such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
About Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the
colon and is characterized by inflammation and ulceration of the lining of
the colon. Sy
|SOURCE Medarex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved